Vaxcyte, Inc.
825 Industrial Road, Suite 300
San Carlos
CA
94070
United States
Tel: (650) 837-0111
Website: https://vaxcyte.com/
Email: info@Vaxcyte.com
About Vaxcyte, Inc.
Vaxcyte, Inc. (Nasdaq: PCVX) is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent some of the most common and deadly infectious diseases worldwide. Our exclusively licensed cell-free protein synthesis platform and our proprietary know how enable us to design and produce optimized protein carriers and antigens, the critical building blocks of vaccines, in ways that we believe conventional vaccine technologies cannot. Our lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease. Our pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of at least 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease by targeting the keystone pathogen responsible for this chronic, oral inflammatory disease.
97 articles about Vaxcyte, Inc.
-
Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
10/28/2022
Vaxcyte, Inc. (Nasdaq: PCVX) announced today the closing of its previously announced underwritten public offering of 17,812,500 shares of common stock at a public offering price of $32.00 per share and pre-funded warrants to purchase 3,750,000 shares of common stock at a public offering price of $31.999 per underlying share.
-
Vaxcyte Announces Pricing of $600 Million Public Offering
10/26/2022
Vaxcyte, Inc., a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced the pricing of an underwritten public offering of common stock and pre-funded warrants.
-
Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
10/24/2022
Vaxcyte, Inc., a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24, the Company’s investigational 24-valent pneumococcal conjugate vaccine, in healthy adults aged 18-64.
-
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
10/24/2022
Vaxcyte, Inc., a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants.
-
Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults
10/23/2022
Vaxcyte, Inc. announced it will hold a webcast and conference call tomorrow, October 24, 2022, at 8:00 a.m. Eastern Time to provide topline results from its Phase 1/2 proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24, the Company’s investigational 24-valent pneumococcal conjugate vaccine, in healthy adults aged 18-64.
-
Vaxcyte Expands Executive Leadership Team with Key Appointments
10/11/2022
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Mark Wiggins as Chief Business Officer and Jakub Simon as Chief Medical Officer.
-
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older
9/6/2022
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the completion of enrollment in the Phase 2 study evaluating VAX-24 in healthy adults 65 years of age and older.
-
Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update
8/8/2022
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the second quarter ended June 30, 2022 and provided a business update.
-
The FDA has had a busy week, accepting drug applications, approving clinical trials and granting various special designations for Gamida Cell, Cellectis, Scynexis & more.
-
Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs
8/4/2022
Vaxcyte, Inc. (Nasdaq: PCVX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VAX-24, the Company’s 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in adults ages 18 and older.
-
Vaxcyte Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults
7/12/2022
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the completion of enrollment in the Phase 2 portion of the ongoing Phase 1/2 proof-of-concept study evaluating VAX-24 in healthy adults 50 to 64 years of age.
-
Vaxcyte to Present at the Jefferies Healthcare Conference
6/2/2022
Vaxcyte, Inc. today announced that Company management will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2022 at 8:30 a.m. ET / 5:30 a.m. PT.
-
Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update
5/9/2022
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the first quarter ended March 31, 2022 and provided a business update.
-
Vaxcyte to Participate in Upcoming Investor Conferences in May 2022
5/3/2022
Vaxcyte, Inc. announced that Company management will participate in and host one-on-one meetings at the following investor conferences.
-
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look. -
Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference
4/5/2022
Vaxcyte, Inc. today announced that Company management will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 12:45 p.m. ET.
-
Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults
4/4/2022
Vaxcyte, Inc. announced today that the first participants were dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical study evaluating VAX-24 for the prevention of invasive pneumococcal disease (IPD) and pneumonia in adults.
-
Vaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
2/28/2022
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.
-
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
2/23/2022
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that the first participants were dosed in the Phase 1/2 clinical study of VAX-24.
-
Vaxcyte to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
2/17/2022
Vaxcyte, Inc. (Nasdaq: PCVX), today announced that it will report financial results for the fourth quarter and full year 2021 after market close on February 28, 2022. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update.